Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegiclidine PCA dose study for pain control after spinal fusion surgery
ChiCTR2600135782Phase 4Not yet recruiting
- Sponsor
- Affiliated Renhe Hospital of China Three Gorges University
- Start
- Nov 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tigecycline and sufentanil in postoperative pain (4 arms), sponsored by Affiliated Renhe Hospital of China Three Gorges University. Primary endpoint: Area under the curve of VAS pain scores at rest during the first 24 hours postoperatively. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tigecyclinesufentanil
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600135782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135782.